XE-991

Research use only, not for human use.

XE-991 is a potent, selective and orally active blocker of voltage-gated potassium channels Kv7 (KCNQ) that blocks KCNQ1, KCNQ2 and KCNQ2+KCNQ3 with Kd of 0.78, 0.7 and 0.6 uM, respectively.

XE-991 is a potent, selective and orally active blocker of voltage-gated potassium channels Kv7 (KCNQ) that blocks KCNQ1, KCNQ2 and KCNQ2+KCNQ3 with Kd of 0.78, 0.7 and 0.6 uM, respectively; displays 14-fold less potency for KCNQ1+minK current with Kd of 11 uM, enhances hippocampal ACh release from rat brain slices (EC50=490 nM) and is a cognitive enhancer in vivo.Alzheimer Disease Discontinued.

XE 991 dihydrochloride possesses an EC50 of 490 nM for enhancement of [3H]ACh release from rat brain slices, and shows good in vivo potency and duration of action.

——

XE991

Cell Cycle/DNA Damage

Potassium Channel

Potassium Channel

Neurological Disease

Alzheimer Disease

122955-42-4

376.45

C26H20N2O

>98% (HPLC)

——

C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3C2(CC4=CC=NC=C4)CC5=CC=NC=C5.Cl.Cl

10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone

(-20℃)

With Ice Pack

≥ 2 years